REVVITY, INC.
RVTYAPI behind this page
RVTY Q3 2025 request
Playground key active
/api/financials?ticker=RVTY&year=2025&quarter=3
Pick an endpoint and run the request.Income Statement
| Metric | Q3 2025 | Q3 2024 | YoY |
|---|---|---|---|
| Revenue | 698,949 | 684,049 | +2.2% |
Show Product Lines breakouts |
|||
| Product | 573,225 | 579,997 | -1.2% |
| Service | 125,724 | 104,052 | +20.8% |
Show Business Segments breakouts |
|||
| Diagnostics [Member] | 356,127 | 345,249 | +3.2% |
| Diagnostics [Member] · Americas | 129,190 | 116,849 | +10.6% |
| Diagnostics [Member] · Asia | 107,872 | 121,477 | -11.2% |
| Diagnostics [Member] · Europe | 119,065 | 106,923 | +11.4% |
| Diagnostics [Member] · Immunodiagnostics [Member] | 212,739 | 211,566 | +0.6% |
| Diagnostics [Member] · Reportable Segment Revenue [Member] | 356,127 | 345,249 | +3.2% |
| Diagnostics [Member] · Reproductive health [Member] | 143,388 | 133,683 | +7.3% |
| Life Sciences [Member] | 342,822 | 338,800 | +1.2% |
| Life Sciences [Member] · Americas | 178,087 | 185,476 | -4.0% |
| Life Sciences [Member] · Asia | 81,403 | 78,209 | +4.1% |
| Life Sciences [Member] · Europe | 83,332 | 75,115 | +10.9% |
| Life Sciences [Member] · Life Sciences Solutions [Member] | 290,541 | 295,455 | -1.7% |
| Life Sciences [Member] · Reportable Segment Revenue [Member] | 342,822 | 338,800 | +1.2% |
| Life Sciences [Member] · Software [Member] | 52,281 | 43,345 | +20.6% |
Show Geography breakouts |
|||
| Americas | 307,277 | 302,325 | +1.6% |
| Asia | 189,275 | 199,686 | -5.2% |
| Europe | 202,397 | 182,038 | +11.2% |
Show Major goods/service lines [Axis] breakouts |
|||
| Immunodiagnostics [Member] | 212,739 | 211,566 | +0.6% |
| Life Sciences Solutions [Member] | 290,541 | 295,455 | -1.7% |
| Reproductive health [Member] | 143,388 | 133,683 | +7.3% |
| Software [Member] | 52,281 | 43,345 | +20.6% |
Show Segment Reporting [Axis] breakouts |
|||
| Reportable Segment Revenue [Member] | 698,949 | 684,049 | +2.2% |
| Cost of Revenue | 324,345 | 299,233 | +8.4% |
Show Product Lines breakouts |
|||
| Product | 280,731 | 256,551 | +9.4% |
| Service | 43,614 | 42,682 | +2.2% |
| Selling, General & Administrative | 241,911 | 237,521 | +1.8% |
| Research & Development | 50,797 | 49,144 | +3.4% |
| Operating Income | 81,896 | 98,151 | -16.6% |
| Interest And Other Expense Net | 26,211 | -2,206 | +1288.2% |
| Income Before Taxes | 55,685 | 100,357 | -44.5% |
| Income Tax Expense (Benefit) | 8,464 | 6,971 | +21.4% |
| Income Loss From Continuing Operations | 47,221 | 93,386 | -49.4% |
| Income Loss From Discontinued Operations Net Of Tax | -569 | 981 | -158.0% |
| Net Income | 46,652 | 94,367 | -50.6% |
Show Equity Components breakouts |
|||
| Retained Earnings | 46,652 | 94,367 | -50.6% |
| Income Loss From Continuing Operations Per Basic Share | 0.41 | 0.76 | -46.1% |
| Income Loss From Discontinued Operations Net Of Tax Per Basic Share | -0.01 | 0.01 | -200.0% |
| EPS (Basic) | 0.4 | 0.77 | -48.1% |
| Income Loss From Continuing Operations Per Diluted Share | 0.41 | 0.76 | -46.1% |
| Income Loss From Discontinued Operations Net Of Tax Per Diluted Share | -0.01 | 0.01 | -200.0% |
| EPS (Diluted) | 0.4 | 0.77 | -48.1% |
| Wtd Avg Shares (Basic) | 115,411 | 122,810 | -6.0% |
| Wtd Avg Shares (Diluted) | 115,463 | 123,026 | -6.1% |
| Non-Operating Income (Expense) | 26,211 | -2,206 | +1288.2% |
| Interest Expense | 22,771 | 24,383 | -6.6% |
| Interest Income | -6,925 | -22,764 | +69.6% |
| Comprehensive Income | 24,324 | 204,386 | -88.1% |
Balance Sheet
| Metric | Q3 2025 | Q3 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 931,386 | 1,229,778 | -24.3% |
| Accounts Receivable | 680,259 | 602,141 | +13.0% |
| Inventory | 379,917 | 404,570 | -6.1% |
| Other Assets Current | 152,226 | 211,917 | -28.2% |
| Total Current Assets | 2,143,788 | 2,448,406 | -12.4% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 497,088 | 517,932 | -4.0% |
| Operating Lease Right-of-Use Assets | 171,078 | 149,305 | +14.6% |
| Goodwill | 6,600,631 | 6,558,660 | +0.6% |
Show Business Segments breakouts |
|||
| Diagnostics [Member] | 1,962,799 | — | — |
| Life Sciences [Member] | 4,637,832 | — | — |
| Other Non-Current Assets | 300,441 | 332,223 | -9.6% |
| Total Assets | 12,138,952 | 12,769,737 | -4.9% |
| Intangible Assets | 2,425,926 | 2,763,211 | -12.2% |
Show Finite and Indefinite Lived Intangible Assets by Major Class [Axis] breakouts |
|||
| Core Technology [Member] | 737,116 | — | — |
| Customer Relationships | 1,629,304 | — | — |
| Licensing Agreements | 8,092 | — | — |
| Patents | 1,338 | — | — |
| Trade Names And Trademarks [Member] | 50,076 | — | — |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 2,425,926 | 2,763,211 | -12.2% |
| Current Liabilities | |||
| Current Portion of Long-Term Debt | 583,844 | 1,045 | +55770.2% |
Show Fair Value Hierarchy breakouts |
|||
| Fair Value Inputs Level2 · 1.875 Percent Ten Year Senior Unsecured Notes [Member] | 583,654 | — | — |
| Accounts Payable | 175,800 | 176,407 | -0.3% |
| Accrued Liabilities | 463,099 | 510,488 | -9.3% |
| Total Current Liabilities | 1,222,743 | 687,940 | +77.7% |
| Non-Current Liabilities | |||
| Long-Term Debt | 2,630,693 | 3,185,699 | -17.4% |
| Other Non-Current Liabilities | 755,155 | 845,998 | -10.7% |
| Operating Lease Liabilities | 154,465 | 128,399 | +20.3% |
| Total Liabilities | 4,763,056 | 4,848,036 | -1.8% |
| Long-Term Debt (Q) | — | — | — |
Show Fair Value Hierarchy breakouts |
|||
| Fair Value Inputs Level2 | 2,630,693 | 3,185,699 | -17.4% |
| Fair Value Inputs Level2 · 1.900% Senior Unsecured Notes due 2028 [Member] | 497,911 | — | — |
| Fair Value Inputs Level2 · 2.250% Senior Unsecured Notes due in 2031 [Member] | 496,320 | — | — |
| Fair Value Inputs Level2 · 2.55 Percent Senior Unsecured Notes due in 2031 [Member] | 397,905 | — | — |
| Fair Value Inputs Level2 · 3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member] | 845,386 | — | — |
| Fair Value Inputs Level2 · 3.625 Percent Senior Unsecured Notes due in 2051 [Member] | 396,031 | — | — |
| Fair Value Inputs Level2 · Senior Unsecured Notes [Member] | 3,217.2 | — | — |
Show Debt Instrument breakouts |
|||
| Line of Credit, Maturing January 7, 2030 | 3,035 | — | — |
| Stockholders' Equity | |||
| Common Stock | 114,030 | 122,091 | -6.6% |
| Additional Paid In Capital Common Stock | 1,477,890 | 2,272,405 | -35.0% |
| Retained Earnings | 5,963,781 | 5,759,120 | +3.6% |
| Accumulated Other Comprehensive Income | -179,805 | -231,915 | +22.5% |
| Total Stockholders' Equity | 7,375,896 | 7,921,701 | -6.9% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -179,805 | -231,915 | +22.5% |
| Additional Paid In Capital | 1,477,890 | 2,272,405 | -35.0% |
| Common Stock | 114,030 | 122,091 | -6.6% |
| Retained Earnings | 5,963,781 | 5,759,120 | +3.6% |
| Total Liabilities & Equity | 12,138,952 | 12,769,737 | -4.9% |
Cash Flow Statement
| Metric | YTD Q3 2025 | YTD Q3 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Restructuring Chargesand Changesin Estimates | 24,368 | 22,119 | +10.2% |
| Depreciation & Amortization | 302,261 | 322,816 | -6.4% |
| Stock-Based Compensation | 26,918 | 32,756 | -17.8% |
| Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | -59 | 6,006 | -101.0% |
| Amortization Of Financing Costs And Discounts | 3,560 | 5,051 | -29.5% |
| Change In Fair Value Of Financial Securities | 3,484 | -13,975 | +124.9% |
| Foreign Currency Transaction Gain Loss Unrealized | 222 | -1,063 | +120.9% |
| Change in Accounts Receivable | -41,643 | 33,291 | -225.1% |
| Change in Inventory | 12,493 | 26,817 | -53.4% |
| Change in Accounts Payable | 270 | -24,782 | +101.1% |
| Increase Decrease In Accrued Liabilities And Other Operating Liabilities | -68,990 | -114,236 | +39.6% |
| Net Cash Provided By Used In Operating Activities Continuing Operations | 406,996 | 489,488 | -16.9% |
| Cash Provided By Used In Operating Activities Discontinued Operations | -6,023 | -35,419 | +83.0% |
| Net Cash from Operations | 400,973 | 454,069 | -11.7% |
| Investing Activities | |||
| Capital Expenditures | -53,351 | -62,194 | +14.2% |
| Purchases Of Investments And Notes Receivables | -29 | -4,337 | +99.3% |
| Proceeds From Divestiture Of Businesses | 229 | — | — |
| Net Cash Provided By Used In Investing Activities Continuing Operations | -53,151 | 645,969 | -108.2% |
| Cash Provided By Used In Investing Activities Discontinued Operations | 56,250 | 147,522 | -61.9% |
| Net Cash from Investing | 3,099 | 793,491 | -99.6% |
| Financing Activities | |||
| Debt Issuance Costs | -2,474 | — | — |
| Proceeds From Repayments Of Other Debt | -158 | -10,771 | +98.5% |
| Payment For Contingent Consideration Liability Financing Activities | -3,838 | -8,832 | +56.5% |
| Proceeds From Stock Options Exercised | 2,632 | 6,173 | -57.4% |
| Share Repurchases | -652,530 | -184,421 | -253.8% |
| Payments Of Dividends Common Stock | -24,845 | -25,915 | +4.1% |
| Net Cash from Financing | -681,213 | -935,245 | +27.2% |
| Supplemental | |||
| Restricted Cash Current | 1,189 | 1,030 | +15.4% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 45,264 | 4,120 | +998.6% |
| Net Change in Cash | -231,877 | 316,435 | -173.3% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 932,575 | 1,230,808 | -24.2% |
Values in thousands USD. Source: SEC EDGAR 10-Q filing.